CA-ESRI
20.4.2022 14:02:25 CEST | Business Wire | Press release
Capturing and sharing life's experiences today often requires multiple platforms and tools, which can result in disjointed storytelling. To serve creators' needs to control their dynamic, interactive narratives in one place, Esri , the global leader in location intelligence, today released StoryMaps, a powerful, personal storytelling tool. The product extends Esri's creative capabilities to anyone who wants to tell their story and share it.
Using Esri's mapping technology, this new software brings the geographic approach to any content that creators are passionate about. From documenting their ancestral journey to capturing aspects of daily life or planning a first big post-pandemic trip, StoryMaps helps capture life's moments in a way worthy of those experiences.
"At Esri, we understand that sharing stories is a part of life, that everyone is a storyteller," said Jack Dangermond, Esri founder and president. "Every moment and memory we treasure is connected to a specific location, which is why we're making it easier to transport people anywhere in the world through richer storytelling."
Esri allows authors to control their narratives with built-in privacy to protect data and automatic content ownership and create them in versatile ways that reflect the experiences themselves. People can creatively combine text with multimedia like images, videos, audio, and links to easily share their personal experiences, hobbies, family history, ancestry, portfolios, travels, and more.
The National Geographic Society (NGS)—which for more than 130 years has been illuminating and protecting the world through science, exploration, education, and storytelling—is partnering with Esri to bring StoryMaps to its members.
"The National Geographic Society has a long legacy of storytelling, and it remains fundamental to our mission work today as we further our understanding of our planet and each other," said Jill Tiefenthaler, National Geographic Society chief executive officer. "Our partnership with Esri enriches this legacy, empowering our members to share their unique stories and experiences through this innovative geospatial tool."
Esri designed StoryMaps to enable everyone with varying digital skills to create custom content without requiring cartography or web design experience. StoryMaps allows authors to
- Build a story in one place. Make versatile stories of any length using your assets (text, photos, videos, audio, etc.) or leverage Unsplash for ready-to-use images.
- Publish and share your story with any audience. Make a private journal, create a shareable unlisted link for family and friends, or publish on all popular social media platforms. Authors can also embed stories on websites and blogs.
- Add custom interactive maps. Bring readers along your journey by adding a map with graphics and pop-ups or create a thematic map to visualize trends.
- Incorporate engaging features. Display content in different ways using flexible components including a timeline, image gallery, swipe, and quotes. All content can be organized into collections that act like folders.
- Customize the look. Choose from built-in themes or customize a design with a different font, color, and layout options.
- Keep it current. Update and publish stories easily with new features and capabilities every two weeks. Future features will include geo-ready data from wearables to show off your latest outdoor activities.
A free basic plan is available with essential storytelling capabilities to ensure all storytellers have access at any time. When new users sign up, they have free access to Premium features with enhanced storytelling capabilities for the first 30 days. After, they can decide to purchase a monthly or annual Premium subscription to StoryMaps at $10 or $100, respectively, or downgrade to the free, basic storytelling option.
To explore StoryMaps, read stories , and get started, visit storymaps.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, StoryMaps, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005532/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom